Inclusion Criteria

Inclusion criteria:

- Confirmed diagnosis of adenocarcinoma of the prostate

- Patients with metastatic hormone refractory prostate cancer

- Patients that have had at least one, but not more than two prior cytotoxic treatments
for prostate cancer

- Evidence of disease progression by at least one of the following

1. two or more lesions on bone scan

2. progressive measurable disease

3. two documented increases in PSA

- Willing to use contraception throughout the study and for 12 weeks after study
completion

Exclusion criteria:

- History or clinical signs of CNS disease

- History of other cancers not curatively treated with no evidence of disease for more
than 5 years

- Prior radiotherapy within 3 weeks of starting study treatment

- Prior radiopharmaceuticals (strontium, samarium)

- Impaired cardiac function

- Heart disease

- Liver or renal disease with impaired function

Other protocol-defined inclusion/exclusion criteria may apply